Understanding how EZH2 affects treatment resistance in prostate cancer
A novel role for EZH2 in PARP regulation and PARPi-resistance in prostate cancer
This study is looking at a protein called EZH2 to understand how it helps prostate cancer resist treatments, with the goal of finding new ways to help men with advanced prostate cancer feel better and respond to new drugs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10979397 on NIH RePORTER |
What this research studies
This research investigates the role of a protein called EZH2 in prostate cancer, particularly how it contributes to resistance against current treatments. By examining the mechanisms of DNA damage and repair, the study aims to identify new therapeutic strategies for men with metastatic prostate cancer. The researchers will analyze the expression levels of EZH2 in cancer cells and explore how this protein influences cancer progression and treatment outcomes. Patients may be involved in trials that test new drugs targeting EZH2 and related pathways.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with metastatic prostate cancer who may have limited treatment options.
Not a fit: Patients with early-stage prostate cancer or those not diagnosed with prostate cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for prostate cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promising results in targeting EZH2 and PARP pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Cao, Qi — Northwestern University at Chicago
- Study coordinator: Cao, Qi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.